BR112021017457A2 - Escetamina para o tratamento de depressão - Google Patents
Escetamina para o tratamento de depressãoInfo
- Publication number
- BR112021017457A2 BR112021017457A2 BR112021017457A BR112021017457A BR112021017457A2 BR 112021017457 A2 BR112021017457 A2 BR 112021017457A2 BR 112021017457 A BR112021017457 A BR 112021017457A BR 112021017457 A BR112021017457 A BR 112021017457A BR 112021017457 A2 BR112021017457 A2 BR 112021017457A2
- Authority
- BR
- Brazil
- Prior art keywords
- esketamine
- depression
- treatment
- methods
- patient
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title abstract 6
- 229960000450 esketamine Drugs 0.000 title abstract 6
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
escetamina para o tratamento de depressão. a presente invenção refere-se a métodos para tratar depressão em um paciente, que compreendem administrar ao paciente que necessita do tratamento uma quantidade terapeuticamente eficaz de escetamina. em algumas modalidades, a depressão é distúrbio depressivo maior ou depressão resistente ao tratamento. em outras modalidades, a quantidade terapeuticamente eficaz é clinicamente comprovada segura e/ou eficaz. também são fornecidos métodos para mitigar o risco, uso indevido ou abuso de escetamina, instruções para uso do produto de escetamina e métodos para vender um produto farmacêutico contendo escetamina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813767P | 2019-03-05 | 2019-03-05 | |
US201962814274P | 2019-03-05 | 2019-03-05 | |
PCT/IB2020/051344 WO2020178653A1 (en) | 2019-03-05 | 2020-02-18 | Esketamine for the treatment of depression |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021017457A2 true BR112021017457A2 (pt) | 2021-11-16 |
Family
ID=72338604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021017457A BR112021017457A2 (pt) | 2019-03-05 | 2020-02-18 | Escetamina para o tratamento de depressão |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230117657A1 (pt) |
EP (1) | EP3934632A4 (pt) |
JP (1) | JP2022524008A (pt) |
CN (1) | CN114126595A (pt) |
AU (1) | AU2020231172A1 (pt) |
BR (1) | BR112021017457A2 (pt) |
CA (1) | CA3131929A1 (pt) |
IL (1) | IL286000A (pt) |
MA (1) | MA55218A (pt) |
MX (1) | MX2021010683A (pt) |
WO (1) | WO2020178653A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3934632A4 (en) * | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | ESKETAMINE FOR THE TREATMENT OF DEPRESSION |
EP4028085A4 (en) * | 2019-09-13 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | INTRANASAL ADMINISTRATION OF ESKETAMINE |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
WO1996025925A1 (en) | 1995-02-24 | 1996-08-29 | Weg Stuart L | Nasal and ocular administration of ketamine to manage pain and for detoxification |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
WO1997007750A1 (en) | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration of ketamine to manage pain and to reduce drug dependency |
FR2739294B1 (fr) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | Embout nasal de securite |
DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
FR2764807B1 (fr) | 1997-06-18 | 1999-08-20 | Valois Sa | Dispositif de distribution nasale d'un produit fluide ou pulverulent |
AU758679B2 (en) | 1998-07-24 | 2003-03-27 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
WO2002024116A1 (en) | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
NZ540282A (en) | 2002-11-18 | 2008-06-30 | Yaupon Therapeutics Inc | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US8082173B2 (en) * | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
JP2007522249A (ja) | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | 精神医学的状態の処置のための、nmdaレセプターアンタゴニストと、抗うつ薬であるmaoインヒビターまたはgadphインヒビターとの併用 |
NZ555501A (en) | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
JP5026411B2 (ja) | 2005-06-01 | 2012-09-12 | エスエイチエル グループ エービー | 薬物送達装置 |
US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
CN101466364A (zh) * | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
WO2007123945A2 (en) | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
JP2009538331A (ja) | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
EP2139848A1 (en) | 2007-04-26 | 2010-01-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
US7745665B2 (en) * | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
KR20110014199A (ko) | 2008-05-13 | 2011-02-10 | 클라라산스, 인크. | 비강 비염 치료용 재조합 인간 cc10 및 이의 조성물 |
US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
AU2011267474B2 (en) | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
WO2013003669A2 (en) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
EP2766339B1 (en) | 2011-10-14 | 2021-06-09 | The United States Of America, as represented by the Secretary, Department of Health & Human Services | The use of (2r, 6r)-hydroxynorketamine and other stereoisomeric hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
JP6285865B2 (ja) | 2011-11-14 | 2018-02-28 | アルファシグマ ソシエタ ペル アチオニ | うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法 |
US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
EP2830604A4 (en) | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
JP6722453B2 (ja) | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | 抗不安薬組成物、製剤および使用方法 |
FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
CN105377371A (zh) | 2013-04-12 | 2016-03-02 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
EP3960162A1 (en) | 2013-08-26 | 2022-03-02 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
WO2015101693A1 (es) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas |
US9610259B2 (en) | 2014-01-14 | 2017-04-04 | Children's Hospital Medical Center | Compositions and methods for treating an autism spectrum disorder |
HUE044928T2 (hu) | 2014-04-17 | 2019-11-28 | Develco Pharma Schweiz Ag | Ketamin orális dózisformája |
RU2697382C2 (ru) | 2014-05-04 | 2019-08-13 | Фирмениш С.А. | Ароматизированные продукты питания и напитки |
FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
EP3725307A1 (en) | 2014-09-15 | 2020-10-21 | Janssen Pharmaceutica NV | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
WO2016109427A1 (en) | 2014-12-31 | 2016-07-07 | Icahn School Of Medicine At Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
WO2016172672A1 (en) | 2015-04-24 | 2016-10-27 | Icahn School Of Medicine At Mount Sinai | Method for treating suicidal ideation |
CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
WO2017003935A1 (en) | 2015-06-27 | 2017-01-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
CN112423789A (zh) * | 2017-12-22 | 2021-02-26 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
EP3934632A4 (en) * | 2019-03-05 | 2022-11-23 | Janssen Pharmaceuticals, Inc. | ESKETAMINE FOR THE TREATMENT OF DEPRESSION |
-
2020
- 2020-02-18 EP EP20766782.5A patent/EP3934632A4/en active Pending
- 2020-02-18 MX MX2021010683A patent/MX2021010683A/es unknown
- 2020-02-18 AU AU2020231172A patent/AU2020231172A1/en active Pending
- 2020-02-18 US US17/436,188 patent/US20230117657A1/en active Pending
- 2020-02-18 BR BR112021017457A patent/BR112021017457A2/pt unknown
- 2020-02-18 JP JP2021552724A patent/JP2022524008A/ja active Pending
- 2020-02-18 CA CA3131929A patent/CA3131929A1/en active Pending
- 2020-02-18 WO PCT/IB2020/051344 patent/WO2020178653A1/en active Application Filing
- 2020-02-18 CN CN202080034094.8A patent/CN114126595A/zh active Pending
- 2020-02-18 MA MA055218A patent/MA55218A/fr unknown
-
2021
- 2021-08-31 IL IL286000A patent/IL286000A/en unknown
-
2022
- 2022-04-01 US US17/711,277 patent/US11883526B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN114126595A (zh) | 2022-03-01 |
EP3934632A1 (en) | 2022-01-12 |
AU2020231172A1 (en) | 2021-09-23 |
US20220362144A1 (en) | 2022-11-17 |
MX2021010683A (es) | 2021-12-10 |
US20230117657A1 (en) | 2023-04-20 |
MA55218A (fr) | 2022-01-12 |
WO2020178653A1 (en) | 2020-09-10 |
US11883526B2 (en) | 2024-01-30 |
CA3131929A1 (en) | 2020-09-10 |
EP3934632A4 (en) | 2022-11-23 |
JP2022524008A (ja) | 2022-04-27 |
IL286000A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
BR112021017457A2 (pt) | Escetamina para o tratamento de depressão | |
BR112021021908A2 (pt) | Composições úteis no tratamento da leucodistrofia metacromática | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112021019262A2 (pt) | Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose | |
BR112023023030A2 (pt) | Composições e métodos para o tratamento de depressão | |
BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
WO2013039956A3 (en) | Compositions and methods for treating mood disorders | |
CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
JP2017524721A5 (pt) | ||
MX2020001254A (es) | Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf. | |
BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
BR112016012141A2 (pt) | "combinações farmacêuticas, uso das mesmas, e embalagem comercial" | |
BR112022010907A2 (pt) | Uso de isatuximab para o tratamento de mieloma múltiplo recidivante e/ou refratário | |
WO2019066548A3 (ko) | 심부전의 예방 또는 치료용 약학적 조성물 |